Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cidara Therapeutics Inc    CDTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/17/2017 08/18/2017 08/21/2017 08/22/2017 08/23/2017 Date
6.475(c) 6.75(c) 6.75(c) 6.75(c) 6.75 Last
239 431 116 782 53 301 63 592 143 055 Volume
+11.64% +4.25% 0.00% 0.00% 0.00% Change
More quotes
Financials ($)
Sales 2017 0,33 M
EBIT 2017 -62,2 M
Net income 2017 -62,4 M
Finance 2017 36,2 M
Yield 2017 -
Sales 2018 0,78 M
EBIT 2018 -69,1 M
Net income 2018 -69,5 M
Finance 2018 60,8 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 233x
EV / Sales2018 67,6x
Capitalization 114 M
More Financials
Company
Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections.Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J.... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of Cidara Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CIDARA THERAPEUTICS INC
08/10 CIDARA THERAPEUTICS : Announces Publication of Results from In Vivo Study Invest..
08/10 CIDARA THERAPEUTICS : reports 2Q loss
08/09 Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Re..
08/09 CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Results of Operations and..
08/09 CIDARA THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
08/02 CIDARA THERAPEUTICS : Announces Publication of Results from In Vivo Study Invest..
08/01 CIDARA THERAPEUTICS : Announces Publication of Results from In Vivo Study Invest..
07/07 CIDARA THERAPEUTICS : to Participate in Anti-Infectives Panel Discussion at the ..
07/06 CIDARA THERAPEUTICS : to Participate in Anti-Infectives Panel Discussion at the ..
06/23 CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Submission of Matters to ..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/16Brokers Issue Forecasts for Cidara Therapeutics, Inc.’s Q3 2017 Earnings $CDT.. 
08/16Wedbush Lowers Cidara Therapeutics Q3 2017 Earnings Estimates to ($1.01) Per .. 
08/15Cidara Therapeutics downgraded by Zacks Investment Research to sell.  
08/14Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.’s FY2018 Ea.. 
08/14Cantor Fitzgerald Sets Cidara Therapeutics FY2018 Earnings Estimates at ($3.0.. 
More tweets
Qtime:10
News from SeekingAlpha
08/21 Scynexis Q2 - Steady As She Goes
08/18 After Hours Gainers / Losers
08/09 Cidara Therapeutics misses by $0.11
06/26 Premarket analyst action - healthcare
06/16 HEALTHCARE GAINERS / LOSERS AS OF 11 : 00 am
Chart CIDARA THERAPEUTICS INC
Duration : Period :
Cidara Therapeutics Inc Technical Analysis Chart | CDTX | US1717571079 | 4-Traders
Technical analysis trends CIDARA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 13,3 $
Spread / Average Target 97%
EPS Revisions
Managers
NameTitle
Jeffrey L. Stein President, Chief Executive Officer & Director
Scott M. Rocklage Chairman
Matthew W. Onaitis CFO, Secretary & General Counsel
Taylor Sandison Chief Medical Officer
Theodore R. Schroeder Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CIDARA THERAPEUTICS INC-35.10%114
AMGEN16.32%124 096
CELGENE CORPORATION10.09%101 932
GILEAD SCIENCES0.70%95 777
REGENERON PHARMACEUTICALS27.48%51 288
VERTEX PHARMACEUTICALS111.05%39 199